Type I interferons as regulators of lung inflammation

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Makris, Spyridon ^a   Paulsen, Michelle ^a,b   Johansson, Cecilia ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Infection; Inflammation; Lung; Pattern recognition receptors; Type I interferons

Indexed keywords

INTERFERON; INTERFERON RECEPTOR; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR;

BACTERIAL INFECTION; CRYPTOCOCCUS NEOFORMANS; GENE EXPRESSION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLUENZA VIRUS; INTRACELLULAR SIGNALING; MYCOSIS; PNEUMONIA; REVIEW;

EID: 85017236177     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00259     Document Type: Review

References (113)

1. Kopf M, Schneider C, Nobs SP. The development and function of lung-resident macrophages and dendritic cells. Nat Immunol (2014) 16:36-44. doi:10.1038/ni.3052
2. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev (2013) 255:25-39. doi:10.1111/imr.12101
3. González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 12:125-35. doi:10.1038/nri3133
4. Swiecki M, Colonna M. Type I interferons: diversity of sources, production pathways and effects on immune responses. Curr Opin Virol (2011) 1:463-75. doi:10.1016/j.coviro.2011.10.026
5. Wack A, Terczynska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol (2015) 16:802-9. doi:10.1038/ni.3212
6. Egli A, Santer DM, O'Shea D, Barakat K, Syedbasha M, Vollmer M, et al. IL-28B is a key regulator of B-and T-cell vaccine responses against influenza. PLoS Pathog (2014) 10:e1004556. doi:10.1371/journal.ppat.1004556
7. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 45:164-71. doi:10.1038/ng.2521
8. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol (2015) 15:87-103. doi:10.1038/nri3787
9. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 34:637-50. doi:10.1016/j.immuni.2011.05.006
10. Loo Y-M, Gale M. Immune signaling by RIG-I-like receptors. Immunity (2011) 34:680-92. doi:10.1016/j.immuni.2011.05.003
11. Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity (2013) 38:855-69. doi:10.1016/j.immuni.2013.05.007
12. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol (2015) 33:257-90. doi:10.1146/annurev-immunol-032414-112240
13. Gürtler C, Bowie AG. Innate immune detection of microbial nucleic acids. Trends Microbiol (2013) 21:413-20. doi:10.1016/j.tim.2013.04.004
14. O'Neill LAJ, Golenbock D, Bowie AG. The history of toll-like receptors-redefining innate immunity. Nat Rev Immunol (2013) 13:453-60. doi:10.1038/nri3446
15. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med (2003) 198:1043-55. doi:10.1084/jem.20031023
16. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 1:398-401. doi:10.1038/80833
17. Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. Nature (2014) 514:372-5. doi:10.1038/nature13590
18. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 314:994-7. doi:10.1126/science.1132505
19. Pichlmair A, Schulz O, Tan CP, Näslund TI, Liljeström P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science (2006) 314:997-1001. doi:10.1126/science.1132998
20. Bruns AM, Leser GP, Lamb RA, Horvath CM. The innate immune sensor LGP2 activates antiviral signaling by regulating MDA5-RNA interaction and filament assembly. Mol Cell (2014) 55:771-81. doi:10.1016/j.molcel.2014.07.003
21. Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science (2015) 347(6227):aaa2630. doi:10.1126/science.aaa2630
22. Wu B, Hur S. How RIG-I like receptors activate MAVS. Curr Opin Virol (2015) 12:91-8. doi:10.1016/j.coviro.2015.04.004
23. Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature (2008) 451:725-9. doi:10.1038/nature06537
24. Paludan SR, Bowie AG. Immune sensing of DNA. Immunity (2013) 38:870-80. doi:10.1016/j.immuni.2013.05.004
25. Chiu Y-H, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell (2009) 138:576-91. doi:10.1016/j.cell.2009.06.015
26. Schattgen SA, Gao G, Kurt-Jones EA, Fitzgerald KA. Cutting edge: DNA in the lung microenvironment during influenza virus infection tempers inflammation by engaging the DNA sensor AIM2. J Immunol (2016) 196:29-33. doi:10.4049/jimmunol.1501048
27. Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal (2012) 5:ra20. doi:10.1126/scisignal.2002521
28. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science (2013) 339:786-91. doi:10.1126/science.1232458
29. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Röhl I, et al. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature (2013) 498:380-4. doi:10.1038/nature12306
30. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science (2013) 339:826-30. doi:10.1126/science.1229963
31. Ablasser A, Schmid-Burgk JL, Hemmerling I, Horvath GL, Schmidt T, Latz E, et al. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature (2013) 503:530-4. doi:10.1038/nature12640
32. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog (2013) 9:e1003773. doi:10.1371/journal.ppat.1003773
33. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 11:373-84. doi:10.1038/ni.1863
34. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol (2014) 14:315-28. doi:10.1038/nri3665
35. Goritzka M, Makris S, Kausar F, Durant LR, Pereira C, Kumagai Y, et al. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. J Exp Med (2015) 212:699-714. doi:10.1084/jem.20140825
36. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5:375-86. doi:10.1038/nri1604
37. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature (2011) 472:481-5. doi:10.1038/nature09907
38. Schoggins JW. Interferon-stimulated genes: roles in viral pathogenesis. Curr Opin Virol (2014) 6:40-6. doi:10.1016/j.coviro.2014.03.006
39. Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity (2012) 36:503-14. doi:10.1016/j.immuni.2012.03.013
40. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 32:513-45. doi:10.1146/annurev-immunol-032713-120231
41. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell (2011) 146:621-32. doi:10.1016/j.cell.2011.06.048
42. De Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, Braniff S-J, et al. Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1. Nat Immunol (2013) 14:901-7. doi:10.1038/ni.2667
43. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature (2005) 434:772-7. doi:10.1038/nature03464
44. Marié I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J (1998) 17:6660-9. doi:10.1093/emboj/17.22.6660
45. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol (2013) 14:36-49. doi:10.1038/nri3581
46. Sancho-Shimizu V, Pérez de Diego R, Jouanguy E, Zhang S-Y, Casanova J-L. Inborn errors of anti-viral interferon immunity in humans. Curr Opin Virol (2011) 1:487-96. doi:10.1016/j.coviro.2011.10.016
47. Zhang S-Y, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev (2008) 226:29-40. doi:10.1111/j.1600-065X.2008.00698.x
48. Ciancanelli MJ, Huang SXL, Luthra P, Garner H, Itan Y, Volpi S, et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science (2015) 348:448-53. doi:10.1126/science.aaa1578
49. Janssen R, Bont L, Siezen CLE, Hodemaekers HM, Ermers MJ, Doornbos G, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis (2007) 196:826-34. doi:10.1086/520886
50. Siezen CLE, Bont L, Hodemaekers HM, Ermers MJ, Doornbos G, Van't Slot R, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes. Pediatr Infect Dis J (2009) 28:333-5. doi:10.1097/INF.0b013e31818e2aa9
51. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature (2012) 484:519-23. doi:10.1038/nature10921
52. Zhang Y-H, Zhao Y, Li N, Peng Y-C, Giannoulatou E, Jin R-H, et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun (2013) 4:1418. doi:10.1038/ncomms2433
53. Pillai PS, Molony RD, Martinod K, Dong H, Pang IK, Tal MC, et al. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. Science (2016) 352:463-6. doi:10.1126/science.aaf3926
54. Ciancanelli MJ, Abel L, Zhang S-Y, Casanova J-L. Host genetics of severe influenza: from mouse Mx1 to human IRF7. Curr Opin Immunol (2016) 38:109-20. doi:10.1016/j.coi.2015.12.002
55. Trinchieri G. Type I interferon: friend or foe? J Exp Med (2010) 207:2053-63. doi:10.1084/jem.20101664
56. Goritzka M, Durant LR, Pereira C, Salek-Ardakani S, Openshaw PJM, Johansson C. Interferon-α/β receptor signaling amplifies early pro-inflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol (2014) 88:6128-36. doi:10.1128/JVI.00333-14
57. Lehmann MH, Torres-Domínguez LE, Price PJR, Brandmüller C, Kirschning CJ, Sutter G. CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA infection. J Leukoc Biol (2016) 99:1057-64. doi:10.1189/jlb.4MA0815-376RR
58. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity (2006) 25:373-81. doi:10.1016/j.immuni.2006.08.007
59. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol (2001) 166:2961-9. doi:10.4049/jimmunol.166.5.2961
60. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol (2003) 4:1009-15. doi:10.1038/ni978
61. Rouzaut A, Garasa S, Teijeira A, González I, Martinez-Forero I, Suarez N, et al. Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-a. Eur J Immunol (2010) 40:3054-63. doi:10.1002/eji.201040523
62. Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, et al. IFN-a enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood (2012) 119:1407-17. doi:10.1182/blood-2011-06-363564
63. Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol (2015) 15:231-42. doi:10.1038/nri3806
64. Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med (2005) 201:1157-67. doi:10.1084/jem.20041930
65. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med (2009) 206:1589-602. doi:10.1084/jem.20090247
66. Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, Matsumoto M, et al. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci U S A (2003) 100:10872-7. doi:10.1073/pnas.1934678100
67. Moltedo B, Li W, Yount JS, Moran TM. Unique type I interferon responses determine the functional fate of migratory lung dendritic cells during influenza virus infection. PLoS Pathog (2011) 7:e1002345. doi:10.1371/journal.ppat.1002345
68. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 17:2619-27. doi:10.1158/1078-0432.CCR-10-1114
69. Tough DF. Modulation of T-cell function by type I interferon. Immunol Cell Biol (2012) 90:492-7. doi:10.1038/icb.2012.7
70. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol (2006) 176:2074-8. doi:10.4049/jimmunol.176.4.2074
71. Chang WLW, Coro ES, Rau FC, Xiao Y, Erle DJ, Baumgarth N. Influenza virus infection causes global respiratory tract B cell response modulation via innate immune signals. J Immunol (2007) 178:1457-67. doi:10.4049/jimmunol.178.3.1457
72. Moseman EA, Wu T, la Torre de JC, Schwartzberg PL, McGavern DB. Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation. Sci Immunol (2016) 1(4). doi:10.1126/sciimmunol.aah3565
73. Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, et al. IFN? is a potent anti-influenza therapeutic without the inflammatory side effects of IFNa treatment. EMBO Mol Med (2016) 8:1099-112. doi:10.15252/emmm.201606413
74. Pfeffer LM. The role of nuclear factor κB in the interferon response. J Interferon Cytokine Res (2011) 31:553-9. doi:10.1089/jir.2011.0028
75. Mattei F, Schiavoni G, Tough DF. Regulation of immune cell homeostasis by type I interferons. Cytokine Growth Factor Rev (2010) 21:227-36. doi:10.1016/j.cytogfr.2010.05.002
76. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology (2006) 344:119-30. doi:10.1016/j.virol.2005.09.024
77. Jaitin DA, Schreiber G. Upregulation of a small subset of genes drives type I interferon-induced antiviral memory. J Interferon Cytokine Res (2007) 27:653-64. doi:10.1089/jir.2006.0162
78. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe (2016) 19:181-93. doi:10.1016/j.chom.2016.01.007
79. Wang BX, Fish EN. The yin and yang of viruses and interferons. Trends Immunol (2012) 33:190-7. doi:10.1016/j.it.2012.01.004
80. Schulz KS, Mossman KL. Viral evasion strategies in type I IFN signaling-a summary of recent developments. Front Immunol (2016) 7:459. doi:10.3389/fimmu.2016.00498
81. Coccia EM, Battistini A. Early IFN type I response: learning from microbial evasion strategies. Semin Immunol (2015) 27:85-101. doi:10.1016/j.smim.2015.03.005
82. Jewell NA, Vaghefi N, Mertz SE, Akter P, Peebles RS, Bakaletz LO, et al. Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo. J Virol (2007) 81:9790-800. doi:10.1128/JVI.00530-07
83. Davidson S, Crotta S, McCabe TM, Wack A. Pathogenic potential of interferon αβ in acute influenza infection. Nat Commun (2014) 5:3864. doi:10.1038/ncomms4864
84. Cormier SA, Shrestha B, Saravia J, Lee GI, Shen L, DeVincenzo JP, et al. Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection. J Virol (2014) 88:9350-60. doi:10.1128/JVI.00818-14
85. Remot A, Descamps D, Jouneau L, Laubreton D, Dubuquoy C, Bouet S, et al. Flt3 ligand improves the innate response to respiratory syncytial virus and limits lung disease upon RSV re-exposure in neonate mice. Eur J Immunol (2015) 46:874-84. doi:10.1002/eji.201545929
86. Marr N, Wang TI, Kam SHY, Hu YS, Sharma AA, Lam A, et al. Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children. J Immunol (2014) 192:948-57. doi:10.4049/jimmunol.1302007
87. Hastings AK, Erickson JJ, Schuster JE, Boyd KL, Tollefson SJ, Johnson M, et al. Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication. J Virol (2015) 89:4405-20. doi:10.1128/JVI.03275-14
88. Duerr CU, McCarthy CDA, Mindt BC, Rubio M, Meli AP, Pothlichet J, et al. Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells. Nat Immunol (2016) 17:65-75. doi:10.1038/ni.3308
89. Haeberle HA, Takizawa R, Casola A, Brasier AR, Dieterich H-J, van Rooijen N, et al. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis (2002) 186:1199-206. doi:10.1086/344644
90. Stifter SA, Bhattacharyya N, Pillay R, Flórido M, Triccas JA, Britton WJ, et al. Functional interplay between type I and II interferons is essential to limit influenza A virus-induced tissue inflammation. PLoS Pathog (2016) 12:e1005378. doi:10.1371/journal.ppat.1005378
91. Hermesh T, Moltedo B, Moran TM, López CB. Antiviral instruction of bone marrow leukocytes during respiratory viral infections. Cell Host Microbe (2010) 7:343-53. doi:10.1016/j.chom.2010.04.006
92. Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL. Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. Immunity (2010) 33:96-105. doi:10.1016/j.immuni.2010.06.016
93. Jiang L, Yao S, Huang S, Wright J, Braciale TJ, Sun J. Type I IFN signaling facilitates the development of IL-10-producing effector CD8(+) T cells during murine influenza virus infection. Eur J Immunol (2016) 46(12):2778-88. doi:10.1002/eji.201646548
94. McNally B, Ye F, Willette M, Flaño E. Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection. J Virol (2013) 87:12916-24. doi:10.1128/JVI.02423-13
95. Chaperot L, Blum A, Manches O, Lui G, Angel J, Molens J-P, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol (2006) 176:248-55. doi:10.4049/jimmunol.176.1.248
96. Herold S, Steinmueller M, Wulffen von W, Cakarova L, Pinto R, Pleschka S, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med (2008) 205:3065-77. doi:10.1084/jem.20080201
97. Parker D, Prince A. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J Immunol (2012) 189:4040-6. doi:10.4049/jimmunol.1201055
98. Qiu H, Fan Y, Joyee AG, Wang S, Han X, Bai H, et al. Type I IFNs enhance susceptibility to Chlamydia muridarum lung infection by enhancing apoptosis of local macrophages. J Immunol (2008) 181:2092-102. doi:10.4049/jimmunol.181.3.2092
99. Dorhoi A, Yeremeev V, Nouailles G, Weiner J III, Jörg S, Heinemann E, et al. Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur J Immunol (2014) 44:2380-93. doi:10.1002/eji.201344219
100. Berry MPR, Graham CM, McNab FW, Xu Z, Bloch SAA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature (2010) 466:973-7. doi:10.1038/nature09247
101. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature (2014) 522:99-103. doi:10.1038/nature13489
102. Hughes CE, Harvey RM, Plumptre CD, Paton JC. Development of primary invasive pneumococcal disease caused by serotype 1 pneumococci is driven by early increased type I interferon response in the lung. Infect Immun (2014) 82:3919-26. doi:10.1128/IAI.02067-14
103. LeMessurier KS, Häcker H, Chi L, Tuomanen E, Redecke V. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog (2013) 9:e1003727. doi:10.1371/journal.ppat.1003727
104. Lee B, Robinson KM, McHugh KJ, Scheller EV, Mandalapu S, Chen C, et al. Influenza-induced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol (2015) 309:L158-67. doi:10.1152/ajplung.00338.2014
105. Ellis GT, Davidson S, Crotta S, Branzk N, Papayannopoulos V, Wack A. TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection. EMBO Rep (2015) 16:1203-18. doi:10.15252/embr.201540473
106. Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of ?d T cells. J Virol (2012) 86:12304-12. doi:10.1128/JVI.01269-12
107. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest (2009) 119:1910-20. doi:10.1172/JCI35412
108. Schliehe C, Flynn EK, Vilagos B, Richson U, Swaminathan S, Bosnjak B, et al. The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection. Nat Immunol (2015) 16:67-74. doi:10.1038/ni.3046
109. Redford PS, Mayer-Barber KD, McNab FW, Stavropoulos E, Wack A, Sher A, et al. Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J Infect Dis (2014) 209:270-4. doi:10.1093/infdis/jit424
110. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 34:213-23. doi:10.1016/j.immuni.2011.02.006
111. Meissner NN, Swain S, Tighe M, Harmsen A, Harmsen A. Role of type I IFNs in pulmonary complications of Pneumocystis murina infection. J Immunol (2005) 174:5462-71. doi:10.4049/jimmunol.174.9.5462
112. Sato K, Yamamoto H, Nomura T, Matsumoto I, Miyasaka T, Zong T, et al. Cryptococcus neoformans infection in mice lacking type I interferon signaling leads to increased fungal clearance and IL-4-dependent mucin production in the lungs. PLoS One (2015) 10:e0138291. doi:10.1371/journal.pone.0138291
113. Biondo C, Midiri A, Gambuzza M, Gerace E, Falduto M, Galbo R, et al. IFN-alpha/beta signaling is required for polarization of cytokine responses toward a protective type 1 pattern during experimental cryptococcosis. J Immunol (2008) 181:566-73. doi:10.4049/jimmunol.181.1.566